fda announcement tirzepatide Important Update on Shortage Arti Thangudu MD|Endocrinologist (Diabetes/Thyroid/Weight Loss)

This means it simultaneously activates three different types of receptors: GLP-1 Receptor (Glucagon-Like Peptide-1) GIP Receptor (Glucose-Dependent Insulinotropic Polypeptide) Glucagon Receptor By targeting these three receptors, Retatrutide offers a multifaceted approach to managing blood glucose levels, enhancing insulin secretion, and potentially promoting weight loss

Nausea You may have nausea with Saxenda

The medication itself is well-established as effective

Who Should Avoid GLP-1 Agonists

This area often contains a larger amount of fatty tissue and may be useful when rotating injection sites

Dual regulation of MMP-2 expression by the type 2 insulin-like growth factor receptor: the phosphatidylinositol 3-kinase/Akt and Raf/ERK pathways transmit opposing signals